Fig. 2From: CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment212Pb-TCMC-YS5 dose selection study in non-tumor bearing nude mice. A Body weight changes post 212Pb-TCMC-YS5 treatment. B Survival of mice post treatmentBack to article page